Tuning the endothelial response: differential release of exocytic cargos from Weibel-Palade Bodies.
View/ Open
Publisher
Publisher URL
DOI
10.1111/jth.14218.
Journal
Journal of Thrombosis and Haemostasis
ISSN
1538-7836
Metadata
Show full item recordAbstract
BACKGROUND:
Endothelial cells harbour specialised storage organelles, Weibel-Palade Bodies (WPBs). Exocytosis of WPB content into the vascular lumen initiates primary haemostasis, mediated by Von Willebrands factor (VWF) and inflammation, mediated by several proteins including P-selectin. During full fusion, secretion of this large haemostatic protein and smaller pro-inflammatory proteins are thought to be inextricably linked.
OBJECTIVE:
To determine if secretagogue-dependent differential release of WPB cargo occurs, and whether this is mediated by the formation of an actomyosin ring during exocytosis.
METHODS:
We used VWF string analysis, leukocyte rolling assays, ELISA, spinning disk confocal microscopy, high-throughput confocal microscopy and inhibitor and siRNA treatments to demonstrate the existence of cellular machinery that allows differential release of WPB cargo proteins.
RESULTS:
Inhibition of the actomyosin ring differentially effects two processes regulated by WPB exocytosis; it perturbs VWF string formation but has no effect on leukocyte rolling. The efficiency of ring recruitment correlates with VWF release; the ratio of release of VWF to small cargoes decreases when ring recruitment is inhibited. The recruitment of the actin ring is time-dependent; fusion events occurring directly after stimulation are less likely to initiate haemostasis than later events, and is activated by PKC isoforms.
CONCLUSIONS:
Secretagogues differentially recruit the actomyosin ring, thus demonstrating one mechanism by which the pro-thrombotic effect of endothelial activation can be modulated. This potentially limits thrombosis whilst permitting a normal inflammatory response. These results have implications for the assessment of WPB fusion, cargo-content release and the treatment of patients with von Willebrand disease.